The Long Island Parkinson's Disease Center

描述（由申请人提供）：帕金森病（PD）是一种常见的退行性神经系统疾病，影响了大约100万美国人。在过去的十年中，PD的治疗和管理的进步越来越多地要求普通神经科医生寻求运动障碍专家的建议，以优化PD患者的护理。随着对帕金森病病理生理认识的不断深入，减缓帕金森病病程的新策略不断涌现。随着这些疗法开始进入临床试验阶段，患者获得这些试验的途径已经并可能继续主要通过PD中心。我们在纽约长岛或附近组建了一个PD专家网络，结合了PD管理的实践经验，广泛的临床试验经验，以及与PD评估治疗的成像方法开发相关的卓越临床研究。凭借这种PD临床试验和研究经验的结合以及非常广泛的人群基础，我们具有独特的优势，可以实现以下具体目标：1)成功参与计划中的PD大规模简单神经保护临床试验。在北岸大学医院（NSUH），我们在成功完成PD临床试验和招募临床研究人员方面有着悠久的记录；2)为计划的临床试验提供有关潜在神经影像学标志物的专业知识。NSUH的功能成像实验室专注于PD治疗的评估。Drs。Feigin和Eidelberg目前由NINDS资助，研究与PD潜在神经保护剂评估直接相关的问题，因此具有独特的视角，可能对未来临床试验的规划有益。为了支持我们能够成功实现这些具体目标的论点，本申请将侧重于五个方面：1)我们集水区的人口统计；2)描述我们目前的PD患者群体和我们的多学科PD中心；3)进一步加强临床试验招募的计划；4)本中心人员通过多中心联合体和独立开展临床试验各方面的经验；5)简要介绍我们在PD治疗方面的影像学研究。

DESCRIPTION (provided by applicant): Parkinson's disease (PD) is a common degenerative neurological disease, affecting approximately 1 million Americans. Advances in the treatment and management of PD over the past ten years have increasingly required general neurologists to seek advice from Movement Disorders specialists in order to optimize PD patient care. With advances in the understanding of the pathophysiology PD, new strategies for slowing the course of PD are emerging. As these therapies have begun to move to clinical trials, patient access to these trials has been and will likely continue to be primarily through PD centers. We have assembled a network of PD specialists in or near Long Island, NY with a combination of practical experience in the management of PD, extensive clinical trial experience, and clinical research excellence related to the development of imaging methods for assessing therapies for PD. With this combination of PD clinical trial and research experience and a very broad population base, we are uniquely positioned to achieve the following Specific Aims: 1) To participate successfully in the planned large-scale simple neuroprotective clinical trial for PD. At North Shore University Hospital (NSUH) we have a long track record of successful completion of clinical trials for PD and of recruitment for clinical research; and 2) To provide expertise regarding potential neuroimaging markers for the planned clinical trial. The functional imaging laboratory at NSUH has focused on the assessment of therapies for PD. Drs. Feigin and Eidelberg are currently funded by NINDS to study issues directly related to the assessment of potential neuroprotective agents for PD and therefore have a unique perspective that may be of benefit for the planning of the future clinical trial. To support our contention that we can successfully achieve these Specific Aims, this application will focus on five areas: 1) The demographics of our catchment area; 2) A description of our current PD patient population and our multidisciplinary PD center; 3) Plans to further enhance recruitment for the planned clinical trial; 4) The experience of our center personnel with all aspects of clinical trial conduct both through multicenter consortiums and independently; and 5) A brief description of our imaging studies of therapies for PD.